NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces it has commenced an investigation of Alkermes plc (“Alkermes” or “the Company”) (NASDAQGS:ALKS) concerning possible violations of federal securities laws.
On April 2, 2018, Alkermes announced receipt of a Refusal to File letter from the U.S. Food and Drug Administration regarding its New Drug Application for ALK 5461. According to Alkermes, the FDA determined it “is unable to complete a substantive review of the regulatory package, based on insufficient evidence of overall effectiveness for the proposed indication, and that additional well-controlled clinical trials are needed prior to the resubmission of the NDA for ALKS 5461.” Following this news, shares of Alkermes were down more 4% on intraday trading on April 3, 2018. To obtain additional information, go to:
http://www.zlkdocs.com/ALKS-Info-Request-Form-6239
or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
